PCM
LYEL icon

Pinz Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Pinz Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,219
Closed -$1.37M – 288
2021
Q2 		$1.37M Buy
+4,219
New +$1.38M 0.41% 66

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Pinz Capital Management's LYEL Position: Q3 2021 in Review

Pinz Capital Management sold out of Lyell Immunopharma (LYEL) in Q3 2021, closing a stake of 4,219 shares — an estimated $1.37M sold.

Pinz Capital Management first reported a position in LYEL in Q2 2021 and held it in 1 quarter. The position peaked at $1.37M in Q2 2021. 62 funds tracked by Wall St. Rank hold LYEL as of Q3 2021.

  • Pinz Capital Management reported no remaining Lyell Immunopharma position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 4,219 Lyell Immunopharma shares in Q3 2021, an estimated $1.37M.
  • Pinz Capital Management first reported a position in Lyell Immunopharma in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Lyell Immunopharma position peaked at $1.37M in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.